1 – 5 of 7
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
Carneiro, Ana LU
; Hahn, Amanda
; Ellmark, Peter
LU
; Enell Smith, Karin
LU
; Schultz, Lena
; Ambarkhane, Sumeet
; Yachnin, Jeffrey
and Ullenhag, Gustav J
(2025)
In Journal for ImmunoTherapy of Cancer
13.
- Contribution to journal › Article
- 2023
-
Mark
Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study
- Contribution to journal › Article
- 2022
-
Mark
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
- Contribution to journal › Article
- 2021
-
Mark
Surgery of metastatic melanoma after systemic therapy–the SUMMIST trial : study protocol for a randomized controlled trial
Holmberg, Carl Jacob ; Katsarelias, Dimitrios ; Jespersen, Henrik ; Carneiro, Ana LU
; Elander, Nils O.
; Helgadottir, Hildur
; Isaksson, Karolin
LU
; Jansson, Malin
; Wirén, Sara
and Ullenhag, Gustav J.
, et al.
(2021)
In Acta Oncologica
60(1).
p.52-55
- Contribution to journal › Letter
-
Mark
Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer
- Contribution to journal › Article